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ABSTRACT
Objective: The purpose of present study was to formulate the gastro-retentive floating tablets of tramadol hydrochloride for enhancement of the 
gastric residence time.
Methods: The floating tablets were prepared by direct compression method and evaluated for hardness, thickness, and friability of the tablets. The 
in vitro drug release studies were performed for different formulations and to optimize the best formulae based on the dissolution profiles.
Results: Fourier transform infrared spectroscopy and differential scanning calorimetry studies revealed that there was no interaction between 
tramadol hydrocholride and excipients. The formulated tablets were evaluated for properties such as weight variation, hardness, thickness, friability, 
drug content, density and floating properties, matrix integrity and complied with United States Pharmacopoeia requirements. The tablets of optimized 
formula had floating lag time of 120, 72, and 96 seconds and the tablets remained in the floating condition for more than 12 hrs. The results of drug 
excipients compatibility studies suggest that there was no significant change in the physical appearance of these blends when stored at 40°C/75% 
relative humidity for 4-week. Among various trial formulations developed with different concentration of polymer F3 (hydroxypropyl methyl cellulose 
[HPMC] K4M with 120 mg of polymer), F5 (HPMC K15M with 100 mg polymer), F11 (polyethylene oxide WSR 303 with 100 mg polymer), were chosen 
as the optimized formulations based on the release profile.
Conclusion: Tramadol hydrochloride floating tablets were successfully made using various polymers for the enhancement of the gastric residence 
time. From the present study, it was concluded that HPMC K4M can be used as an effective polymer for the formulation of floating effervescent tablets 
of highly soluble drug indicating the successful development of sustained release floating drug delivery system.
Keywords: Tramadol hydrochloride, Floating tablets, Polyethylene oxide 303 WSR, Polyethylene oxide N60, Hydroxypropyl methylcellulose K4M, 
Hydroxypropyl methyl cellulose K15M, Hydroxypropyl methyl cellulose K100M.
INTRODUCTION
The oral route is considered most frequent, natural, preferred, 
uncomplicated, convenient, more flexible, safe due to its ease of 
administration, patient acceptance, flexibility in formulation, and cost-
effective manufacturing process. The most of the therapeutic agents 
are, generally effectual when the release is at a fairly constant rate or 
near the absorption sites. The absorption of drug produced results 
in required plasma concentrations leading to reduce side effects and 
optimum efficacy. Controlled drug delivery technology offer many 
advantages, which includes that the increasing therapeutic activity 
compared to the intensity of side effects, reducing the frequency of 
administration thereby achieve the patient compliance, or eliminating 
the need for specialized drug administration (e.g., repeated injections) 
when compared to conventional dosage forms and it shows a typical 
release pattern of drug release for a prolonged period of time by 
maintaining the drug concentration within the therapeutic window 
where the rate of drug release matches the rate of elimination [1-4].
Hydroxypropyl methylcellulose (HPMC) is an odorless, tasteless, white 
or creamy-white fibrous or granular powder and it molecular weight 
ranges from 10,000 to 1,500,000 g/mol. It is used as tablet binder 
(2-5% w/v), emulsifier, rate controlling polymer, stabilizing agent in 
gels, adhesive in plastic bandages, suspending agent, thickening agent 
(0.45-1% concentration, in eye drops and artificial tear solutions), 
viscosity-increasing agent, coating agent, film-former in tablet film 
coating and extended release matrix tablet formulations (generally high 
viscosity grades used). It is used in protective colloids, which prevents 
droplets and particles from coalescing. Commonly, lower viscosity 
grades of polymer are used in aqueous film coating, and higher viscosity 
grades are used in solvent film coating. The concentration varies 
from 2% to 10% w/v depends on the viscosity grade of the polymer. 
Polyethylene oxide molecular weight ranges from 100,000 to 7,000,000 
Daltons, and it is used as mucoadhesive polymer, tablet binder and 
thickening agent [5-8].
Tramadol hydrochloride is a centrally acting synthetic opioid 
analgesic, to treat moderate to severe pain through opoid receptor 
binding as well as inhibition of nor epinephrine and serotonin 
reuptake and it belongs to biopharmaceutical classification system 
class I drug (high soluble- high permeable drug). It has a wide range 
of applications, including treatment of rheumatoid arthritis, restless 
leg syndrome, and fibromyalgia. It has an absolute bioavailability of 
75% and a volume of distribution of approximately 2.7 L/kg. It has an 
elimination half-life of 4-6 hrs and has an absorption zone from the 
upper intestinal tract. The efficacy of the administered dose may get 
diminished due to incomplete drug release from the device above the 
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absorption zone. Hence, it requires multiple daily drug dosage, high 
frequency of dosing to maintain optimum plasma concentrations and 
also having short plasma half-life due to this reason it is a suitable 
drug for gastro retentive formulation. The present system of preparing 
floating drug is that it will remain in gastric region for longer duration 
causing an increase in gastric residence time, which may cause 
improve bioavailability and reduces drug waste. The gastro-retentive 
drug delivery systems can be retained in the stomach for several hours 
and assist in continuously releasing the drug before it reaches the 
absorption window for significantly prolong the predictable period 
of gastric residence time to produce an optimum drug bioavailability 
as well as reduces drug waste without affecting the gastric emptying 
rate. The principal of buoyant preparation offers a simple and practical 
approach to achieve increased gastric residence time for dosage form 
and sustained drug release [5-13]. The present study is was aimed for 
development of gastro retentive floating matrix tablets of tramadol HCl 
using various polymers such as HMC K4M, HPMC K15M, HPMC K100M, 
polyethylene oxide (PEO) 303 WSR and PEO N60 and its comparative 
study was also done.
METHODS
Tramadol hydrochloride was obtained as the gift sample from Matrix 
Laboratories, Bangalore. HPMC K15 M, HPMC K4M, and HPMC 
K100M were procured from Merck chemicals limited, Germany. 
PEO 303 WSR and PEO N60 were purchased from Dow chemical 
company (USA). Other ingredients such as sodium bicarbonate, citric 
acid, magnesium stearate were procured from S.D. Fine chemicals, 
Mumbai.
Drug polymer interaction studies
Fourier transform infrared (FTIR) spectroscopy study
Tramadol hydrochloride and excipients were subjected to compatibility 
study. The drug and polymer were mixed physically in 1:1 ratio and the 
mixtures were placed in sealed vials for 3 months at room temperature. 
The samples were prepared by mixing with potassium bromide and 
placing in the sample holder. The spectra were scanned over the wave 
number range of 4000-400/cm at the ambient temperature.
Differential scanning calorimetry (DSC) analysis
DSC analysis was carried out on pure drug, drug and excipients mixture. 
The accurate amount of samples was weighed into aluminum pans and 
sealed. All samples were run at a heating rate of 10°C/minute over a 
temperature range of 30-300°C in an atmosphere of nitrogen [5].
Standard curve of tramadol HCl
Spectrophotometric method based on the measurement of absorbance 
at 271 nm in 0.1 N HCl was used for the estimation of tramadol 
hydrochloride. 100 mg of the pure drug was dissolved in 100 ml of 
0.1 N HCl (stock solution 1000 μg/ml), from this 10 ml of solution 
was taken, and the volume was adjusted to 100 ml with 0.1 N HCl 
(100 μg/ml). The above solution was subsequently diluted with 0.1 N 
HCl (pH 1.2) to obtain the series of dilutions containing 20, 60, 80, 100, 
120, 140 μg/ml of tramadol HCl solution. The absorbance of the above 
dilutions was measured at 271 nm using the UV spectrophotometer 
(Shimadzu) using 0.1 N HCl as the blank. Then a graph was plotted by 
taking concentration on x-axis and absorbance on y-axis which gives a 
straight line [7].
Preparation of floating tablets
Floating tablets were prepared by direct compression technique using 
different grades of various polymers (HPMC K4M, HPMC K15M, HPMC 
K100M, PEO 303 WSR and PEO N 60) with varying amount (40, 60, and 
80 mg).
All the ingredients (Table 1) except magnesium stearate were 
shifted through sieve ¹40 and blended in mixer uniformly. After that 
mixing thoroughly of drug as well as other components in polybag 
for 15 minutes and magnesium stearate were added for lubrication 
purpose and further mixed for additional 2-3 minutes. The tablets were 




The power sample under test was screened through sieve no. 18 and 
the sample equivalent to 25 g was weighed and filled in a 100 ml 
graduated cylinder and the power was leveled and the unsettled 







The power sample under test was screened through sieve no. 18 and the 
weight of sample equivalent to 25 g filled in 100 ml graduated cylinder. 
The mechanical tapping of cylinder was carried out using tapped 
density tester at a nominal rate of 300 drops per minute for 500 times 
initially and the tapped volume Vo was noted. Tapping was proceeding 
further for an additional tapping 750 times and tapped volume; Vb was 
noted. The difference between two tapping volume was less the 2%; Vb 
was considered as a tapped volume Vf.
The tapped density was calculated in g/cm3 by the formula:
Tapped density=M/Vf
Where,
M=Weight of sample power taken,
Vf=Tapped volume.
Compressibility index
The bulk density, tapped density was measured, and compressibility 





Hausner ratio of the blend was calculated using the following formula:
Hausner ratio=Pt/Po
Fig. 1: Standard curve of tramadol hydrochloride
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r=Radius of the pile.
Characterization of tablets
Drug content
The 20 tablets of each formulation were weighed and powdered. The 
quantity of powder equivalent to 100 mg of tramadol hydrochloride 
was transferred into a 100 ml volumetric flask, and the volume was 
adjusted to 100 ml with 0.1 N HCl. The sample was filtered to remove 
the insoluble excipients. Further, 1 ml of the above solution (filtrate) 
was diluted to 100 ml with 0.1 N HCl, and the absorbance of the 
resulting solution was observed at 271 nm [5].
Hardness
Hardness of the tablet was determined by using the Monsanto hardness 
tester. The lower plunger was placed in contact with the tablet, and a 
zero reading was taken. The plunger was then forced against a spring 
by turning a threaded bolt until the tablet fractured. As the spring was 
compressed a pointer rides along a gauge in the barrel to indicate the 
force required for the tablet to break.
Friability test
Friability was determined by weighing 10 tablets after dusting, placing 
them in the friabilator (Roche friabilator) and rotating the plastic 
cylinder vertically at 25 rpm for 4 minutes. After dusting, the total 
remaining weight of the tablets was recorded and the percent friability 







Twenty tablets were randomly selected from each batch and 
individually weighed. The average weight and standard deviation 
Table 1: Formulation of tramadol floating tablets
Formulation code HPMC K4M (mg) HPMC K15M (mg) HPMC K100M (mg) PEO 303 WSR (mg) Avicel (mg) PEO N60 (mg)
F1 40 - - - 110 -
F2 60 - - - 90 -
F3 80 - - - 70 -
F4 - 40 - - 110 -
F5 - 60 - - 90 -
F6 - 80 - - 70 -
F7 - - 40 - 110 -
F8 - - 60 - 90 -
F9 - - 80 - 70 -
F10 - - - - 110 40
F11 - - - - 90 60
F12 - - - - 70 80
F13 - - - 40 110 -
F14 - - - 60 90 -
F15 - - - 80 70 -
All formulations contains 100 mg of tramadol HCl, 5 mg citric acid, 40 mg of sodium bicarbonate and 5 mg of magnesium stearate. HPMC: Hydroxy propyl methyl 
cellulose, PEO: Polyethylene oxide
Fig. 2: Differential scanning calorimetry thermo gram of pure drug
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of 20 tablets were calculated. The batch passes the test for weight 
variation test if not more the two of the individual tablet weight 
deviate from the average weight by more than the percentage shown 
in the table and none deviate by more than twice the percentage 
shown [5].
Floating property study
The time taken for dosage form to emerge on surface medium called 
floating lag time (FLT) and duration of time by which it constantly 
emerge on surface of the medium is called total floating time. The 
tablets from each formulation batch were placed in the United States 
Pharmacopoeia (USP) Type II dissolution apparatus (Disso 2000, 
Labindia) containing 900 ml 0.1 N HCl of pH 1.2 using paddle at a 
rotational speed of 100 rpm. The temperature of the medium and the 
duration of time by which the tablet constantly remain on the surface 
of medium were noted.
Swelling behavior study of the tablets
The extent of swelling can be measured in terms of %weight gain 
by the tablet. For each formulation batch, tablets were weighed and 
placed in a beaker containing 200 ml 0.1 N HCl of pH 1.2. After each 
hour the tablets were removed from beaker and weighed again up to 










Wt=Weight of tablet at time t hr,
W0=Weight of tablet before immersion.
In vitro dissolution studies
Dissolution of tablets of each batch was carried out using USP Type II 
dissolution apparatus (Disso 2000, Labindia) using paddle. 900 ml of 
0.1 N HCl (pH 1.2) was filled in a dissolution vessel, and the temperature 
of medium were set at 37°C±0.5°C. Tablets were placed in dissolution 
vessel, and the rotational speed of paddle was set at rpm 75. The 10 ml 
of sample was withdrawn at predetermined time interval (0.5, 1, 2, 4, 
6, 8, 10, 12 hrs) and same volume of fresh medium was replaced. The 
samples were analyzed for drug contain against 0.1 N HCl as a blank at a 
Fig. 3: Differential scanning calorimetry thermo gram of pure drug, hydroxypropyl methylcellulose (HPMC) K100M model drug, HPMC 
K100 M physical mixture
Fig. 4: Differential scanning calorimetry thermo gram of pure drug, drug-polyox WSR 303, polyox WSR 303 with physical mixture
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Fig. 5: Differential scanning calorimetry thermo gram of pure drug, drug and avicel PH 102, avicel PH 102 with physical mixture
Fig. 6: Differential scanning calorimetry thermo gram of pure drug, drug and sodium bicarbonate, sodium bicarbonate with 
physical mixture
Fig. 7: Differential scanning calorimetry thermo gram of pure drug, drug and citric acid, citric acid with physical mixture
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wavelength of 271 nm using double beam UV-visible spectrophotometer 
(Shimadzu). The content of drug was calculated using the equation 
generated from the standard curve. The % cumulative drug release was 
calculated.
Drug release kinetics of the matrix tablets
The analysis of drug release mechanism from a pharmaceutical dosage 
form is an important but complicated process. The dissolution data 
is fitted to popular release models such as zero order, first order, 
diffusion, and erosion. The order of drug release from matrix systems 
was described using zero order kinetics or first order kinetics. The 
mechanism of drug release from matrix systems was studied by using 
Higuchi and erosion equations [1].
Zero order release kinetics
It defines a linear relationship between the fractions of drug released 
versus time.
Q=kot
Where, Q is the fraction of drug released at time t and ko is the zero order 
release rate constant. A plot of the fraction of drug released against time 
will be linear if the release obeys zero order release kinetics.
First order release kinetics
Wagner assuming that the exposed surface area of a tablet decreased 
exponentially with time during dissolution process suggested that drug 
Fig. 8: Fourier transform infrared spectroscopy spectrum of tramadol hydrochloride
Fig. 9: Fourier transform infrared spectroscopy spectrum of tramadol hydrochloride, physical mixture of placebo and drug with hydroxy 
propyl methyl cellulose
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release from most slow release tablets could be described adequately 
by apparent first-order kinetics.
In(1−Q)=−k1t
Where, Q is the fraction of drug released at time (t) and k1 is the first 
order release rate constant. A plot of the logarithm of the fraction of 
drug remained against time will be linear if the release obeys first order 
release kinetics.
Higuchi equation
It defines a linear dependence of the active fraction released per unit of 
surface (Q) on the square root of time.
Q=k2t1/2
Where Q is the fraction of drug released at time t, k2is the release rate 
constant. A plot of the fraction of drug released against square root of 
time will be linear if the release obeys Higuchi equation.
Erosion equation
This equation defines the drug release based on tablet erosion alone.
Q=1−(1−k3t)3
Where, Q is the fraction of drug released at time t, k3 is the release rate 
constant. A plot between [1−(1−Q1/3] against time will be linear if the 
release obeys erosion equation [4-25].
RESULTS
Drug polymer interaction study
FTIR analysis
The spectra of physical mixture were compared with the infrared 
spectrum of pure drug. From the infrared spectra, it is clearly evident 
that there were no interactions of the drug. Infrared spectrum of the 
pure drug shows the characteristic peaks at 3346.2/cm and 702.77/
cm. Spectrum of drug and excipients exhibited peaks at similar ranges. 
This confirms the undisturbed structure of the drug in the formulation. 
This proves the fact that there is no potential incompatibility of the 
drug with the polymers used in the formulations. Hence, the formula for 
preparing tramadol hydrochloride floating tablets can be reproduced in 
the industrial scale without any apprehension of possible drug-polymer 
interactions.
DSC thermograms
DSC thermograms revealed and confirmed that there was no interaction 
between drug and polymer.
Flow properties of formulations
The bulk density and tapped density of formulation F1-F15 ranges from 
0.312 to 0.458 and 0.354 to 0.542 g/cc, respectively. The bulk density 
and tapped density for optimized formulation (F3) was found to be 
0.315 and 0.362 g/cc, respectively, which were reported in Table 3. 
The values of carr’s index, hausner’s ratio, angle of repose which were 
reported in Table 3 indicated good to fair flow properties as per USP 
Fig. 10: Fourier transform infrared spectroscopy spectrum of tramadol hydrochloride, physical mixture of placebo and drug 
with polyox
Table 2: Visual observation for drug-excipient ratios for compatibility study








Drug White powder White powder White powder White powder White powder
Drug and HPMC K4 M Cream powder Cream powder Cream powder Cream powder Cream powder
Drug and HPMC K15 M Cream powder Cream powder Cream powder Cream powder Cream powder
Drug and HPMC K100 M Cream powder Cream powder Cream powder Cream powder Cream powder
Drug and POLYOX 303 WSR White powder White powder White powder White powder White powder
Drug and AVICEL pH 1 O2 White powder White powder White powder White powder White powder
Drug and sodium bicarbonate White powder White powder White powder White powder White powder
Drug and citric acid White powder White powder White powder White powder White powder
Drug and magnesium stearate White powder White powder White powder White powder White powder
RH: Relative humidity, HPMC: Hydroxy propyl methyl cellulose
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limits. For optimized formulation, free flow properties were categorized 
as good flow which was reported in Table 3.
Floating behavior
All these formulations remained floating for more than 6 hrs which 
were indicated in Table 4. Optimized formulation (F3) also remained 
floating for 12 hrs as indicated in Table 4. The floating properties of 
tablets may be attributed to their low density.
Swelling studies
The results were shown in Table 5. It revealed that all the formulations 
swell to certain degree after coming in contact with simulated gastric fluid.
Post compression parameters
The tablets were evaluated for various tableting characteristics. All 
formulations were passed the evaluation tests and showed the compared 
satisfactory results. The obtained results were shown in Table 6.
In vitro drug release
Among various trial formulations developed with different 
concentration of polymer and excipients, F3 (HPMC K4 M with 120 mg 
of polymer), F5 (HPMC K15 M with 100 mg polymer), F11 (Polyox WSR 
303 with 100 mg polymer), were chosen as the optimized formulations 
based on the release profile. The cumulative % drug release of all 
formulations from F1 to F15 was shown in Fig. 11 and Table 7.
Table 3: Flow properties of formulation blends from F1 to F15
Formulation code Bulk density* (g/cm3) Tapped density *(g/cm3) Compressibility 
index (CI)* (%)
Hausner’s ratio* Angle of repose* (θ)
F1 0.312±0.12 0.354±0.01 11.86±0.04 1.134±0.13 330.45±0.43
F2 0.314±0.21 0.358±0.12 12.29±0.16 1.140±0.07 29.89±0.23
F3 0.315±0.13 0.362±0.12 12.98±0.09 1.149±0.02 30.25±0.26
F4 0.314±0.11 0.360±0.14 12.77±0.07 1.146±0.15 28.6±0.24
F5 0.318±0.12 0.366±0.13 13.11±0.11 1.150±0.06 29.45±0.34
F6 0.326±0.11 0.365±0.14 13.42±0.05 1.155±0.12 30.23±0.24
F7 0.449±0.13 0.530±0.11 15.28±0.14 1.180±0.04 26.82±0.34
F8 0.452±0.14 0.536±0.14 15.67±0.06 1.185±0.11 29.81±0.32
F9 0.453±0.11 0.538±0.11 15.79±0.17 1.187±0.03 30.42±0.36
F10 0.455±0.15 0.536±0.12 15.11±0.06 1.178±0.08 28.90±0.37
F11 0.455±0.10 0.538±0.13 15.42±0.05 1.182±0.05 29.65±0.33
F12 0.458±0.12 0.542±0.14 15.49±0.15 1.183±0.12 30.65±0.31
F13 0.455±0.11 0.536±0.16 15.11±0.06 1.178±0.08 28.90±0.24
F14 0.455±0.12 0.538±0.17 15.42±0.12 1.182±0.05 29.65±0.25
F15 0.458±0.01 0.542±0.21 15.49±0.13 1.183±0.12 30.65±0.27
*Indicates±SD (n=3), SD: Standard deviation
Table 4: Characterization of floating properties
Formulation code FLT* (s±SD) Floating duration (hrs) Matrix integrity
F1 15±2.2 6 +
F2 100±2.7 8 +
F3 120±3.1 12 +
F4 69±2.5 8 +
F5 72±2.4 12 +
F6 180±2.6 12 +
F7 68±2.7 12 +
F8 90±3.2 12 +
F9 200±3.4 12 +
F13 42±3.2 12 +
F14 101±3.1 12 +
F15 164±3.4 12 +
*Indicates±SD (n=3), SD: Standard deviation
Table 5: Swelling studies for formulations
Formulation code Percentage of swelling* (%± SD)
1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h
F1 Tablets showed maximum amount of erosion
F2 0.75±0.34 0.98±0.23 1.08±0.22 1.87±0.08 1.98±0.34 2.08±0.02 2.29±0.27 2.46±0.09
F3 0.88±0.26 1.06±0.32 1.04±0.23 1.96±0.32 2.11±0.27 2.35±0.03 2.38±0.23 2.54±0.23
F4 Tablets showed maximum amount of erosion
F5 1.33±0.36 1.47±0.37 1.73±0.32 1.68±0.47 1.81±0.32 2.06±0.02 2.32±0.22 2.56±0.02
F6 1.38±0.39 1.49±0.23 1.84±0.42 1.95±0.49 2.00±0.40 2.10±0.32 2.44±0.23 2.75±0.43
F7 1.36±0.25 1.56±0.22 1.74±0.38 2.03±0.32 2.31±0.25 2.43±0.36 2.55±0.24 2.77±0.43
F8 1.34±0.43 1.67±0.25 1.85±0.36 2.17±0.33 2.41±0.42 2.54±0.34 2.69±0.23 2.78±0.45
F9 1.84±0.23 2.00±0.37 2.39±0.34 2.40±0.34 2.43±0.28 3.07±0.30 3.23±0.24 3.33±0.49
F13 2.10±0.43 2.15±0.32 2.20±0.31 2.45±0.34 2.67±0.29 2.89±0.32 3.12±0.24 3.45±0.28
F14 2.15±0.28 2.24±0.42 2.67±0.23 2.89±0.43 2.98±0.27 3.05±0.28 3.58±0.25 3.74±0.27
F15 2.19±0.32 2.45±0.22 2.75±0.45 2.99±0.43 3.14±0.24 3.66±0.27 3.91±0.25 3.96±0.34
*(% ±SD), n=3, SD: Standard deviation
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Drug release kinetics
In vitro release data of optimized formulations were fitted to various 
kinetic models like zero order, first order, Higuchi, Korsmeyer-Peppas. 
Optimized formulations followed anomalous type (non-Fickian transport) 
and in vitro drug release was found to have followed Higuchi kinetics.
DISCUSSION
The maximum absorbance was observed at 271 nm. The standard 
curve was found to be linear in the range of 20-60 μg/ml and having 
the regression coefficient value of 0.99. Drug-excipient compatibility 
studies were done by FTIR and DSC, characteristic stretching bands 
were slightly varied after pre-formulation study, revealing no chemical 
interaction and drug-excipient compatibility studies shown that the 
slight broadening as well as shifting of endothermic peak due to melting 
effect of hydrophilic retardants. The granules of fifteen formulations 
(F1-F15) were evaluated for flow properties such as angle of repose, 
bulk density, tapped density, Carr’s index and Hausner’s ratio showed 
the blend has good flow property. It was found that all the granules 
have good flow property as they showed the angle of repose value was 
between 26 and 30°, represents good flow property. Carr’s index value 
and Hausner’s ratio were found that good flow property. There is no 
significant difference in friability values (% w/w) between prepared 
tablets consisting of various polymers and compressed at same force. 
The compression force is effected the friability and hardness. Tablets 
compressed with higher force tend to have slightly lower friability 
when compared with the ones compressed with smaller force due to 
the increased hardness of the tablets and increased binding ability of 
HPMC when compressed under larger forces. Tablets prepared with 
larger compression force produces harder tablets. Hardness is effected 
the floating time. Harder tablets tend to have longer FLT compared to 
softer tablets, which could be explained by the lower ability of water 
to penetrate and to hydrate the outer polymer layer and to provoque 
Table 6: Physical characterization of tablets






Friability* (% w/w) Drug content*(%)
F1 300.9±0.5 4.65±0.5 5-6 0.390±0.06 100.54±0.34
F2 300.89±0.2 4.61±0.2 5-6 0.415±0.11 98.44±0.13
F3 300.9±0.5 4.59±0.3 5-6 0.426±0.03 99.68±0.09
F4 300.2±0.3 4.62±0.4 5-6 0.524±0.04 99.77±0.05
F5 300.3±0.8 4.56±0.5 5-6 0.541±0.01 100.9±0.12
F6 300.2±0.1 4.62±0.4 5-6 0.390±0.11 99.95±0.02
F7 300.7±1.2 4.52±0.8 5-6 0.344±0.05 99.98±0.05
F8 300.2±0.3 4.65±0.2 5-6 0.314±0.06 100.09±0.15
F9 300.6±0.3 4.61±0.6 5-6 0.325±0.12 100.5±0.08
F10 300.4±0.2 4.58±0.4 5-6 0.076±0.0.02 101.5±0.12
F11 298.9±1.5 4.59±0.2 5-6 0.072±0.04 100.9±0.04
F12 299.3±0.5 4.57±0.5 5-6 0.066±0.03 99.54±0.11
F13 300.6±0.3 5.54±0.5 5-6 0.050±0.02 100.67±0.13
F14 300.4±0.3 5.53±0.2 5-6 0.040± 100.56±0.14
F15 299.6±0.2 5.56±0.5 5-6 0.060± 99.64±0.13
*Mean±SD; n=3, SD: Standard deviation
Fig. 11: In vitro dissolution profile of various formulations 
(F1-F15)
Table 7: In vitro dissolution profile of various formulations (F1-F15)
Formulation code Time (hrs)*
0 0.5 1 2 4 6 8 10 12 
F1 0 46.8±1.12 87.22±0.34 98.05±0.54 98.35±0.04 99.35±0.35 100±0.02 - -
F2 0 21.16±0.16 30.32±0.35 44.05±0.54 71.05±0.06 90.57±0.32 100.34±0.01 - -
F3 0 15.07±0.14 21.93±0.27 33.83±0.43 52.29±0.08 69.07±0.56 82.34±0.03 95.3±0.45 101.02±0.54
F4 0 38.56±0.43 52.45±0.29 74.65±0.54 81.32±0.09 96.78±0.55 99.98±0.32 100±0.44 -
F5 0 13.54±0.32 21.47±0.34 33.83±0.58 52.83±0.11 71.2±0.66 86.15±0.35 96.52±0.55 101.56±0.54
F6 0 11.86±0.54 20.86±0.35 34.59±0.12 54.27±0.14 72.42±0.76 81.42±0.37 90.88±0.54 97.13±0.57
F7 0 25.74±0.54 33.37±0.38 48.02±0.36 66.78±0.16 79.29±0.82 88.74±0.38 96.52±0.55 100.03±0.53
F8 0 23±0.56 27.12±0.37 40.39±0.54 59.61±0.18 71.51±0.34 80.2±0.37 88.74±0.56 95±0.52
F9 0 19.74±0.32 24.62±0.36 36.45±0.57 51.23±0.19 65.43±0.35 72.56±0.35 79.46±0.57 89.61±0.38
F13 0 20.25±0.34 27.27±0.35 39.17±0.58 56.1±0.18 73.8±0.33 89.35±0.36 100.8±0.58 101.89±0.45
F14 0 15.37±0.35 22.85±0.34 33.98±0.45 51.22±0.17 63.12±0.32 73.95±0.33 83.71±0.59 89.81±0.43
F15 0 12.24±0.34 20.1±0.35 28.03±0.47 38.41±0.18 48.32±0.54 61.29±0.34 74.25±0.67 83.1±0.45
F10 0 22.25±0.76 29.27±0.37 42.17±0.63 50.1±0.21 75.8±0.45 92.35±0.33 99±0.63 101.89±0.43
F11 0 10.37±0.56 18.85±0.34 30.98±0.92 47.22±0.27 59.12±0.43 67.95±0.35 80.71±0.66 89.81±0.43
F12 0 14.24±0.49 18.1±0.33 29.03±0.97 42.41±0.53 52.32±0.44 60.29±0.37 72.25±0.62 87.1±0.43
*Indicates±SD (n=3), SD: Standard deviation
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effervescent reaction which will provide floating of the dosage form and 
the total floating duration remained buoyant over the media for periods 
more than 8 hrs.
Swelling index of tablets composed of the various polymer/blend but 
compressed with different forces, it could be concluded that softer 
tablets have higher swelling capability compared to harder tablets 
which could be due to the lower inter-particle connections in the tablets 
and higher porosity which lead to greater water uptake and greater and 
faster swelling degree of the matrix. Tablets containing HPMC K4M 
tend to swell less compared with the tablets than HPMC K15M due to 
the highest solubility and erodability (due to low viscosity) of HPMC 
K4M than tablets containing HPMC K15M (due to high viscosity). All 
formulations of tablets formed a gel layer fast enough which give them 
firmness and provided controlled release of active compound in a 
period of 8 hrs by both diffusions through the pores of the hydrated 
polymer layer and erosion of the tablets surface. There are no significant 
differences into the dissolution profiles of tablets containing the same 
polymer/blend and compressed by different forces, nor of the tablets 
containing different polymers compressed by the same force.
CONCLUSION
In the present study, an attempt was made to formulate and optimize 
gastro retentive floating effervescent system of tramadol hydrochloride 
using HPMC and PEO as polymers. The pre-formulation studies were 
done initially from which it was inferred that model drug has fair flow 
properties. The formulated tablets were evaluated for properties such 
as weight variation, hardness, thickness, friability, drug content, density 
and floating properties, matrix integrity. The formulated floating tablets 
complied with USP requirements. The tablets of optimized formula 
had FLT of 120, 72, and 96 seconds and the tablets remained in the 
floating condition for more than 12 hrs. The results of drug excipients 
compatibility studies suggest that there was no significant change in 
the physical appearance of these blends, when stored at 40°C/75% 
relative humidity for 4 weeks. From the present study, it was concluded 
that HPMC K4 M can be used as effective polymer for the formulation of 
floating effervescent tablets of highly soluble drug indicating successful 
development of sustained release floating drug delivery system.
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